Koffiekamer Terug naar discussie overzicht

OTC fonds RDGL

1. kar.b 18 oktober 2018 19:37

   auteur info

   • kar.b

     Lid sinds: 29 sep 2010

     Laatste bezoek: 04 jul 2023

   • Aanbevelingen

     Ontvangen: 6

     Gegeven: 5

   •    Aantal posts: 239

   Het aandeel met de meeste potentie is RDGL
   
   Het staat genoteerd aan de Amerikaanse OTC
   De koers is nu ongeveer 0,014 dollar
   Zij presenteren binnenkort een product dat bepaalde vormen van kanker behandeld. Potentie is hier oneindig groot...
   
   The strategic market sector of Vivos Inc. is therapeutic isotope applications. Currently, the Company is engaged in the development of RadioGel™, a Yttrium-90 based brachytherapy device, for the treatment of tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside the treatment area.
   
   The company is engaging the FDA for permission to use RadioGel™ for the treatment of advanced basal and squamous cell skin cancers. The RadioGel™ Veterinary Solutions division of Vivos is focused on demonstrating the safety and therapeutic effectiveness for different animal cancers in four different university veterinary hospitals. Vivos is positioning itself so that after this demonstration phase, The Company can begin to generate revenues through the sale of RadioGel™ to private animal clinics.
   
   The Company currently is outsourcing material aspects of manufacturing of its product in the United States and intends to enter into licensing arrangements outside of the United States for the manufacturing and distribution of RadioGel™ in other countries.
   
   What is RadioGel™?
   
   RadioGel™ is a hydrogel liquid containing tiny Yttrium-90 phosphate particles to be injected into a tumor. This hydrogel is a liquid at temperatures below body temperature but begins to gel, harden, upon injection as the temperature increases to normal body temperature, thereby locking the particles in place. The particles emit a very high concentrated and contained beta irradiation to kill the tumor. The beta radiation has a short penetration distance so there is minimal collateral damage to healthy tissues outside of the injected area.
   RadioGel™ also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to 6 weeks or more to deliver a full course of radiation therapy. This is an outpatient treatment much safer to the personnel treating the patient than competing brands and the patient can go home immediately with no risk to family members.
   
2. winst is winst 19 oktober 2018 15:20

   auteur info

   • winst is winst

     Lid sinds: 02 jul 2011

     Laatste bezoek: 03 jan 2024

   • Aanbevelingen

     Ontvangen: 47

     Gegeven: 2

   •    Aantal posts: 3.047

   Heb ze een aantal weken en ziet er goed uit.
   maar voorlopig blijft het otc en al gedeelte winst genomen.
   
3. kar.b 21 oktober 2018 22:09

   auteur info

   • kar.b

     Lid sinds: 29 sep 2010

     Laatste bezoek: 04 jul 2023

   • Aanbevelingen

     Ontvangen: 6

     Gegeven: 5

   •    Aantal posts: 239

   Afgelopen vrijdag een plus van ruim 50 procent....Check out investorshub...veel goede DD....gaat nog flink door stijgen...
4. winst is winst 25 november 2022 20:27

   auteur info

   • winst is winst

     Lid sinds: 02 jul 2011

     Laatste bezoek: 03 jan 2024

   • Aanbevelingen

     Ontvangen: 47

     Gegeven: 2

   •    Aantal posts: 3.047

   nog steeds long,komen spannende tijden aan.